Description

Release Date: 07/08/2009
Expiration Date: 07/08/2010

Lung cancer is the leading cause of cancer related mortality in the United States in both men and women. NSCLC accounts for approximately 87% of all new lung cancer diagnoses and the majority of patients either present with incurable disease or relapse after curative therapy leading to the dismal 5 year survival of only 16%.

The management of metastatic NSCLC has evolved a great deal over the last decade and novel therapeutics, combined with chemotherapy, are now the standard of care for patients with newly diagnosed disease. In addition, we have learned a great deal about the role of tumor histology and cancer genetics in predicting responses to both standard chemotherapy and novel agents. Lastly, the role of second line chemotherapy is expanding as we are discovering the potential benefits of its earlier administration.

Presented by:

Learning Objectives

1. Select patients who are appropriate for novel therapeutics in combination with standard chemotherapy for first line therapy of metastatic NSCLC.

2. Evaluate the potential pros and cons of early second line chemotherapy in metastatic NSCLC.

3. Recognize the impact of histology on the use of both novel therapeutics and standard chemotherapy in patients with metastatic NSCLC.

4. Summarize the implications of genetic testing for predicting response to novel therapeutics in patients with metastatic NSCLC.

Faculty

Jennifer Temel, MD
Director, Fellowship Program
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School

Rebecca Heist, MD, MPH
Medical Oncologist, Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center


Alice Shaw, MD, PhD
Attending Physician
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School

General Information

Dr. Temel is a consultant for Merck. She receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website http://www.mghcme.org/.

Dr. Heist is on the Scientific Advisory Board for Novartis. She receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website http://www.mghcme.org/.

Dr. Shaw is on the Scientific Advisory Board for Pfizer. She is a consultant for Wyeth, Merck and GlaxoSmithKline. She receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website www.mghcme.org.

Accreditation

This activity was planned and produced in accordance with ACCME essentials. Beth Israel Medical Center and St. Luke's-Roosevelt Hospital Center are accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

Beth Israel Medical Center designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Resolution of Conflict of Interest (COI)
It is the policy of Beth Israel Medical Center and St. Luke's and Roosevelt Hospitals has implemented a process to resolve COI for each CME activity. In order to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public, the EOCME has resolved the conflict by Peer Review.

Supporters

Our evidence based curriculum is supported by educational grants from:

• 
  
•